Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02151409
Recruitment Status : Completed
First Posted : May 30, 2014
Last Update Posted : February 9, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This trial is conducted in Europe. The aim of this trial is to develop a complement system targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic autoimmune diseases.

Condition or disease Intervention/treatment Phase
Inflammation Systemic Lupus Erythematosus Rheumatoid Arthritis Healthy Drug: NNC 0151-0000-0000 Drug: placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.
Study Start Date : June 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NNC 0151-0000-0000 i.v.
Dose escalation trial
Drug: NNC 0151-0000-0000
A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.

Experimental: NNC 0151-0000-0000 s.c.
Dose escalation trial
Drug: NNC 0151-0000-0000
A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels

Placebo Comparator: Placebo Drug: placebo
A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).

Primary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: Week 0-10 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • Body weight (BW) below or equal to 110.0 kg
  • Body Mass Index (BMI) 20.0 - 27.0 kg/m^2, both inclusive
  • Good state of health: evidenced by medical history, physical examination and results of laboratory examinations

Exclusion Criteria:

  • History of known or suspected cardiovascular diseases including: supine systolic blood pressure (BP) above or equal to 140 mmHg or below 90 mm Hg, diastolic BP above oe equal to 90 mm Hg or below 40 mm Hg, heart rate (HR) in supine position above 100 beats/minute or below 45 beats/minute
  • Hepatic insufficiency: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above Upper Limit of Normal (ULN) (retesting is permitted within one week if first test is elevated but below 1.5 fold ULN)
  • Renal insufficiency: Serum creatinine above ULN
  • Positive for humane immunodeficiency virus (HIV) (by test)
  • Positive for hepatitis B (HBV) or hepatitis C (HCV) (by test)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02151409

Layout table for location information
Novo Nordisk Investigational Site
Groningen, Netherlands, 9728 NZ
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Publications of Results:
The first-in-human trial of the humanised monoclonal antibody NNC 0151-0000-0000 blocking the C5a receptor (C5aR). EULAR (European League Against Rheumatism) 2009; Country: Denmark City: Copenhagen

Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT02151409    
Other Study ID Numbers: NN8209-1940
2008-000731-18 ( EudraCT Number )
First Posted: May 30, 2014    Key Record Dates
Last Update Posted: February 9, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Pathologic Processes
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases